Nanobiotix S.A. (NBTX)
Nanobiotix S.A. Statistics
Share Statistics
Nanobiotix S.A. has 47.11M shares outstanding. The number of shares has increased by 4.96% in one year.
| Shares Outstanding | 47.11M |
| Shares Change (YoY) | 4.96% |
| Shares Change (QoQ) | -6.46% |
| Owned by Institutions (%) | 12.88% |
| Shares Floating | 37.19M |
| Failed to Deliver (FTD) Shares | 3.28K |
| FTD / Avg. Volume | 31.84% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.92 and the forward PE ratio is -7.63. Nanobiotix S.A.'s PEG ratio is -0.06.
| PE Ratio | -1.92 |
| Forward PE | -7.63 |
| PS Ratio | -11.28 |
| Forward PS | 1.1 |
| PB Ratio | -1.99 |
| P/FCF Ratio | -6.42 |
| PEG Ratio | -0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Nanobiotix S.A..
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.04, with a Debt / Equity ratio of -0.77.
| Current Ratio | 1.04 |
| Quick Ratio | 1.04 |
| Debt / Equity | -0.77 |
| Debt / EBITDA | -0.87 |
| Debt / FCF | -2.5 |
| Interest Coverage | -8.46 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $-107.49K |
| Profits Per Employee | $-630.85K |
| Employee Count | 108 |
| Asset Turnover | -0.17 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 101K |
| Effective Tax Rate | -0.15% |
Stock Price Statistics
The stock price has increased by -45.72% in the last 52 weeks. The beta is 1.55, so Nanobiotix S.A.'s price volatility has been higher than the market average.
| Beta | 1.55 |
| 52-Week Price Change | -45.72% |
| 50-Day Moving Average | 3.44 |
| 200-Day Moving Average | 4.09 |
| Relative Strength Index (RSI) | 42.06 |
| Average Volume (20 Days) | 10.31K |
Income Statement
In the last 12 months, Nanobiotix S.A. had revenue of -11.61M and earned -68.13M in profits. Earnings per share was -1.44.
| Revenue | -11.61M |
| Gross Profit | -11.61M |
| Operating Income | -68.39M |
| Net Income | -68.13M |
| EBITDA | -58.32M |
| EBIT | -59.95M |
| Earnings Per Share (EPS) | -1.44 |
Balance Sheet
The company has 49.74M in cash and 50.9M in debt, giving a net cash position of -1.17M.
| Cash & Cash Equivalents | 49.74M |
| Total Debt | 50.9M |
| Net Cash | -1.17M |
| Retained Earnings | -68.13M |
| Total Assets | 67.42M |
| Working Capital | 2.53M |
Cash Flow
In the last 12 months, operating cash flow was -19.55M and capital expenditures -848K, giving a free cash flow of -20.4M.
| Operating Cash Flow | -19.55M |
| Capital Expenditures | -848K |
| Free Cash Flow | -20.4M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 100%, with operating and profit margins of 589.13% and 586.89%.
| Gross Margin | 100% |
| Operating Margin | 589.13% |
| Pretax Margin | 586.02% |
| Profit Margin | 586.89% |
| EBITDA Margin | 502.4% |
| EBIT Margin | 589.13% |
| FCF Margin | 175.72% |
Dividends & Yields
NBTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NBTX is $8, which is 152.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $8 |
| Price Target Difference | 152.4% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -2.87 |
| Piotroski F-Score | 3 |